Mirum Pharmaceuticals, Inc. (MIRM) Phase 3 EXPAND Meets Primary, All Secondary Endpoints
Mirum Pharmaceuticals (MIRM) announced its Phase 3 EXPAND study of LIVMARLI met primary and secondary endpoints, including biliary atresia analyses, with no new safety concerns. The company plans a U.S. supplemental New Drug Application in H1 2027. According to the company, this extends LIVMARLI's potential beyond ALGS and PFIC to other ultra-rare cholestatic pruritus conditions.
How this was made
The 30-second read
Why it matters
The data validates the drug's efficacy, setting up a U.S. supplemental NDA filing and possible EU expansion, which could materially affect valuation.
Market read
Positive trial data is a catalyst for biotech stocks; investors will watch the upcoming sNDA filing.
What to watch
Potential competition in cholestatic pruritus space and payer reimbursement uncertainty.
Background
Mirum Pharmaceuticals announced successful Phase 3 results for its LIVMARLI program, extending its indication beyond ALGS and PFIC.
Ticker impact
Mirum reported its Phase 3 EXPAND study of LIVMARLI met primary and all secondary endpoints, a first disclosure of positive trial data.
upward pressure as the market prices in the successful trial outcome and upcoming sNDA.
First report of pivotal trial results; clinical data is material for biotech valuations.
Market effects
Strengthens the rare‑disease biotech sector, may boost peer valuations.
U.S. biotech market sees modest uplift.
Limited to investors focused on rare‑disease therapeutics.
Counterpoint
If regulatory hurdles delay the sNDA, the rally could be short‑lived.
Key entities
- companyMirum Pharmaceuticals, Inc.
Biotech firm developing LIVMARLI for ultra‑rare cholestatic pruritus.
